Imagen de Portada

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Iskandar Idris
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism Now
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
por: David C. Klonoff, et al.
Publicado: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
por: Darren Lau, et al.
Publicado: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
por: Tae Hyeon Kim, et al.
Publicado: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
por: Yunwen Xu, et al.
Publicado: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
por: Filip K. Knop, et al.
Publicado: (2024)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
por: Karen L. Jones, et al.
Publicado: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
por: Fu‐Shun Yen, et al.
Publicado: (2025)

Evaluating biased agonism of glucagon‐like peptide‐1 ( GLP ‐1) receptors to improve cellular bioenergetics: A systematic review
por: Sabrina Wong, et al.
Publicado: (2025)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
por: Lucas Duchemin, et al.
Publicado: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
por: Irl B. Hirsch, et al.
Publicado: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
por: Ruoyang Jiao, et al.
Publicado: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
por: Julio Rosenstock, et al.
Publicado: (2025)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
por: Conner E. Johnson, et al.
Publicado: (2024)